used a multi-omics computational framework to analyze gene expression profiles and drug sensitivity in 30 AML patients, identifying SMARCA4 as a driver of sensitivity to topoisomerase II inhibitors (40). Here, SMARCA4 is linked to acute myeloid leukemia.